Clinical Trials Logo

De Novo Transplant Disease clinical trials

View clinical trials related to De Novo Transplant Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01744470 Active, not recruiting - Clinical trials for De Novo Transplant Disease

Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)

ADEQUATE
Start date: May 2012
Phase: Phase 4
Study type: Interventional

This prospective, interventional, open label, randomized, multicenter study was designed to determine the risk/benefit ratio of a 50 % reduction of Advagraf® daily dose, 4 months after transplantation. Randomized patients are to be stable with their tacrolimus daily dose required to reach targeted tacrolimus trough levels. Based on Month-3 eligibility assessments, patients will be randomized in two groups (1:1): patients with 50 % reduction of the daily dose of Advagraf® 4 months after transplantation, and patients kept on their usual dose. The benefit/risk ratio will include the assessment of renal function, histological lesions from both alloreactivity and CNI nephrotoxicity, and safety data (metabolic and infectious diseases).